| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 05/30/2002 | CA2429442A1 Aminothiazoles and their use as adenosine receptor antagonists |
| 05/30/2002 | CA2429383A1 Selective dopamine d4 receptor agonists for treating sexual dysfunction |
| 05/30/2002 | CA2429313A1 Novel sulfonamide-substituted pyrazolopyridine derivatives |
| 05/30/2002 | CA2429309A1 Novel carbamate-substituted pyrazolopyridine derivatives |
| 05/30/2002 | CA2429260A1 Medicinal compositions comprising cs-866 and a diuretic |
| 05/30/2002 | CA2429257A1 Antidiabetic compositions containing a biguanide and a sulfonamide |
| 05/30/2002 | CA2428386A1 Use of a triple combination comprising a 5ht3 antagonist, a 5ht4 agonist and a laxative for promoting intestinal lavage |
| 05/30/2002 | CA2428191A1 Acid derivatives useful as serine protease inhibitors |
| 05/30/2002 | CA2427334A1 Methods and compositions for the treatment of diseases of the eye |
| 05/30/2002 | CA2427330A1 Inhibitors of abc drug transporters at the blood-brain barrier |
| 05/30/2002 | CA2427184A1 Combination comprising an agent decreasing vegf activity and an agent decreasing egf activity |
| 05/30/2002 | CA2426939A1 Cystoskeleton-associated proteins |
| 05/30/2002 | CA2426929A1 Treatment of osteoporosis |
| 05/30/2002 | CA2426601A1 Cyanoguanidine prodrugs |
| 05/30/2002 | CA2398924A1 Isolated human phosphatase proteins, nucleic acid molecules encoding human phosphatase proteins, and uses thereof |
| 05/30/2002 | CA2363951A1 Modulating ramp activity |
| 05/30/2002 | CA2363935A1 Therapy for andropause using estrogen agonists/antagonists and testosterone |
| 05/29/2002 | EP1208847A2 Pharmaceutical compositions for treatment of transplant rejection, autoimmune or inflammatory conditions comprising cyclosporin A and 40-O(2-hydroxyethyl)-rapamycin |
| 05/29/2002 | EP1208842A2 Regulation of the immune system |
| 05/29/2002 | EP1208840A2 Combination of fluorouracil and a methylol transfer agent for the treatment of tumor metastases and cancer |
| 05/29/2002 | EP1208838A2 Pure S(+)isomer fluoxetine |
| 05/29/2002 | EP1208701A2 Communications system |
| 05/29/2002 | EP1208384A2 Methods and compositions for modulating oxidized ldl transport |
| 05/29/2002 | EP1208380A2 Cancer associated antigens and uses therefor |
| 05/29/2002 | EP1208228A2 Differential gene expression in specific regions of the brain in neurodegenerative diseases |
| 05/29/2002 | EP1208225A2 Single nucleotide polymorphisms in mitochondrial genes that segregate with alzheimer's disease |
| 05/29/2002 | EP1208201A2 Compositions and methods for the treatment of immune related diseases |
| 05/29/2002 | EP1208196A1 15571, a novel gpcr-like molecule of the secretin-like family and uses thereof |
| 05/29/2002 | EP1208195A2 Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| 05/29/2002 | EP1208101A1 Vitronectin receptor antagonists useful for the treatment of strokes |
| 05/29/2002 | EP1207908A1 Method of treating body insect infestation |
| 05/29/2002 | EP1207907A2 Compositions for treating viral infections, and methods therefor |
| 05/29/2002 | EP1207902A2 USE OF GROWTH HORMONE (hGH) FOR THE TREATMENT OF SEXUAL FUNCTIONAL DISTURBANCES |
| 05/29/2002 | EP1207900A2 Dose of an angiogenic factor and method of administering to improve myocardial blood flow |
| 05/29/2002 | EP1207899A2 Treatment of allergic rhinitis |
| 05/29/2002 | EP1207888A2 Use of paclitaxel and of steroid derivatives as aromatase inhibitors for the treatment of cancer |
| 05/29/2002 | EP1207884A2 Use of cgrp antagonists and cgrp release inhibitors for controlling menopausal hot flashes |
| 05/29/2002 | EP1207882A1 Acyclic and cyclic amine derivatives |
| 05/29/2002 | EP1207879A1 Nicotine receptor agonists in stem cell and progenitor cell recruitment |
| 05/29/2002 | EP1207878A2 Treatment of migraine by the administration of alpha-lipoic acid or derivatives thereof |
| 05/29/2002 | EP1207877A1 Anti-inflammatory actions of cytochrome p450 epoxygenase-derived eicosanoids |
| 05/29/2002 | EP1207876A1 Use of proteinase inhibitor in order to inhibit the cleavage of growth factor precursor |
| 05/29/2002 | EP1207874A1 Methods of treating proliferative disorders |
| 05/29/2002 | EP1207873A1 Methods of inhibiting osteoclast activity |
| 05/29/2002 | EP1207872A1 Ibuprofen-containing softgels |
| 05/29/2002 | EP1207869A2 Antimycotic drug |
| 05/29/2002 | EP1207863A2 New uses for potassium channel openers, such as the treatment of epilepsy |
| 05/29/2002 | EP1207862A2 Arthritis treatment |
| 05/29/2002 | EP1207861A1 Treatment of fungal infections utilizing a fungal growth medium |
| 05/29/2002 | EP1207856A2 Coformulation methods and their products |
| 05/29/2002 | EP1207851A1 Topical organic ectoparasiticidal formulations |
| 05/29/2002 | EP1207840A1 Pharmaceutical compositions and methods for reducing the appearance of cellulite |
| 05/29/2002 | EP1207809A1 Metering and packaging of controlled release medication |
| 05/29/2002 | EP0889971B1 Phosphatase modulator |
| 05/29/2002 | EP0799023B1 Use of flavonoids as immunomodulating or immuno-protective agents in cosmetic and dermatological preparations |
| 05/29/2002 | EP0678021B1 Methods for the improvement of cognition with partial agonists of the glycine nmda receptor complex |
| 05/29/2002 | CN1351713A Diagnosis and treatment of atherosclerosis and coronary heart disease |
| 05/29/2002 | CN1351661A Compounds |
| 05/29/2002 | CN1351601A Heterocyclic compounds binding chemotactic factor receptor |
| 05/29/2002 | CN1351599A Indole-type derivatives as inhibitors of P38 kinase |
| 05/29/2002 | CN1351593A Substituted polycyclic aryl and heteroaryl pyrymidinones useful as anticoagulants agents |
| 05/29/2002 | CN1351502A Multivaleng dengue virus vaccine |
| 05/29/2002 | CN1351496A Medicaments containing inhibitors of cell-volume regulated human kinase h-sgk |
| 05/29/2002 | CN1351494A Microgranules insoluble in gastric fluid, method for obtaining same and pharmaceutical preparations |
| 05/29/2002 | CN1351490A Use of 15-deoxyspergualin for the treatment of hyperreactive inflammatory diseases and autoimmune diseases |
| 05/29/2002 | CN1085687C Polymeric matrices and their uses in pharmaceutial compositions |
| 05/28/2002 | US6395788 Methods and compositions for treating or preventing sleep disturbances and associated illnesses using very low doses of cyclobenzaprine |
| 05/28/2002 | US6395784 Obesity, hypercholesterolemia, atherosclerosis, thyroid cancer, hypothyroidism, osteoporosis, depression, arrhythmia, and congestive heart failure treatment |
| 05/28/2002 | US6395783 Treatment of PCP addiction and PCP addiction-related behavior |
| 05/28/2002 | US6395781 Reducing vascular diameter |
| 05/28/2002 | US6395780 Prevent glucose degradation |
| 05/28/2002 | US6395770 Method and compositions for administering taxanes orally to human patients |
| 05/28/2002 | US6395767 Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
| 05/28/2002 | US6395764 Nosal decongestion, respiratory system disorders |
| 05/28/2002 | US6395763 Antitumor, anticancer agents; immunosuppressant |
| 05/28/2002 | US6395752 Method of treating depression using 1-threo-methylphenidate |
| 05/28/2002 | US6395746 Methods of treating ophthalmic, otic and nasal infections and attendant inflammation |
| 05/28/2002 | US6395743 Aids therapy |
| 05/28/2002 | US6395736 Compositions and methods for the treatment of anorectal disorders |
| 05/28/2002 | US6395727 Method of treating Bulimia Nervosa and related eating disorders by administration of atypical antipsychotic medications |
| 05/28/2002 | US6395725 Prevention or reverse drug resistance |
| 05/28/2002 | US6395719 Methods for increasing levels of acetylcholine |
| 05/28/2002 | US6395715 Antitumor agents |
| 05/28/2002 | US6395712 Sensitization of HER-2/neu overexpressing cancer cells to chemotherapy |
| 05/28/2002 | US6395530 LLG polypeptides of the triacylglycerol lipase family, and compositions and methods for their use in enzymatic hydrolysis, and protein and gene therapies |
| 05/28/2002 | US6395502 Method and means for modulating PGE synthase activity |
| 05/28/2002 | US6395498 Methods of identifying compounds that modulate body weight using the OB receptor |
| 05/28/2002 | US6395313 Ngali nut oil |
| 05/28/2002 | US6395310 Composition containing embryo bud and seed coat from rice and fruit body of Ganoderma lucidum for treating diabetes |
| 05/28/2002 | US6395277 Method and compositions for the treatment of cerebral palsy |
| 05/28/2002 | US6394812 Vivo induction for enhanced function of isolated hepatocytes |
| 05/28/2002 | CA2248006C Activated linkers and methods for making and purifying the same |
| 05/28/2002 | CA2071651C A parenterally administrable drug having thrombolytic activity and containing protein c |
| 05/28/2002 | CA2048300C Compositions containing a 4-quinolone derivative complexed with a divalent metal ion |
| 05/23/2002 | WO2002040700A2 Corticotropin releasing factor receptor 2 deficient mice and uses thereof |
| 05/23/2002 | WO2002040683A2 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 05/23/2002 | WO2002040671A2 Immunoglobulin superfamily proteins |
| 05/23/2002 | WO2002040666A2 Fat regulated genes, uses thereof, and compounds for modulating same |
| 05/23/2002 | WO2002040649A1 Slo2 and slo4, novel potassium channel proteins from human brain |
| 05/23/2002 | WO2002040629A2 Promoters exhibiting endothelial cell specificity and methods of using same |